Model DetailsLung tumor
Model Name |
Lung tumor | Strain |
CD-1 |
Tumor Inducing Agent(s) |
Chemical/Drug : 3'-azido-3'-deoxythymidine (AZT) |
Tumor Synonyms |
lung neoplasm • lung tumor |
Strain Synonyms |
outbred CD-1 • Swiss CD-1® • CD1 nontransgenic • Charles River CD-1 • Swiss CD-1 • Crl:CD-1®(ICR) • outbred CD1 • (Swiss) CD-1 • CD1 • Crl:CD-1(ICR)BR • ICR Crj:CD-1 • random-bred Crl:CD-1(ICR)BR • CD-1 outbred • Crl:CD-1 (ICR) BR • Crj:CD-1(ICR) • ICR(CD-1) • Crl: CD-1 (ICR) BR • ICR |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Lung | Male |
13.0% (3 of 23 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
45% (9 of 20 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
87.5% (7 of 8 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
57.1% (16 of 28 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
37.3% (19 of 51 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
46.2% (12 of 26 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
36.4% (8 of 22 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
66.7% (4 of 6 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
42.9% (12 of 28 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
44.4% (24 of 54 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
14.3% (3 of 21 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
46.2% (6 of 13 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
73.7% (14 of 19 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
62.5% (20 of 32 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
43.4% (23 of 53 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
37.5% (9 of 24 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
58.8% (10 of 17 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
70% (7 of 10 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
63.0% (17 of 27 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
51.0% (26 of 51 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
50% (7 of 14 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
25% (2 of 8 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
56.25% (9 of 16 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
70% (7 of 10 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
36.8% (7 of 19 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
53.8% (7 of 13 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
13.3% (2 of 15 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
42.9% (6 of 14 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |